Pharmplanet became the official distributor of German drug Curavisc for joints treatment

KYIV, Ukraine - Nov. 12, 2014 - PRLog -- In the product portfolio of the pharmaceutical company Pharmplanet there appeared an original drug Curavisc from the German manufacturer Сurasan, specializes in the development of regenerative medicine area.

Curavisc in clinical practice used primarily for the treatment of osteoarthritis - disease damaging the articular cartilage owing to increase viscoelasticity and the quality of synovial fluid. The drug is in a ready-to-use syringe is used as an implant for articular synovial fluid injection. Curavisc is based on highly purified sodium hyaluronate of European quality without causing adverse reactions.

The entry on European market of Curavisc took place in 2005. Today, the medicine is widely used in daily practice, not only for the treatment of osteoarthritis, but also in the treatment of chronic pain syndrome. Hyaluronic acid is also used successfully after arthroscopy (minimally invasive surgical procedure) to reduce postoperative pain and accelerate the healing process. Clinical studies in Europe confirm that Curavisc effectively eliminates pain associated with the wear of the articular cartilage, improves joint mobility and slows cartilage destruction.

According to the German manufacturer, the choice of a partner to promote Curavisc on the Ukrainian market is not accidental. This decision was made based on the successful experience of Pharmplanet in the area of arthrology, its impeccable business reputation and high dynamics of development.

Launch of Curavisc on the domestic market is an important step in the realization of Pharmplnet mission. Attracting the latest developments and international experience, the company Pharmplanet provides the Ukrainians with modern high-quality medicines and effective solutions for health.

Curavisc is available in pharmacies chains since November.